Malaria treatment: Quinidine discontinued, Artesunate now first-line treatment for severe malaria in US
by Press Release from Outbreak News Today on (#4C1X5)
CDC is issuing new guidance to clinicians for the treatment of severe malaria cases in the United States (U.S.). This change in treatment protocol is necessary because the only FDA-approved intravenous (IV) antimalarial drug in the U.S., quinidine, has been discontinued by the manufacturer and will no longer be available. As of April 2019, artesunate, ["]
The post Malaria treatment: Quinidine discontinued, Artesunate now first-line treatment for severe malaria in US appeared first on Outbreak News Today.